Q-omics provides the consensus-scored H3-3B profile across patient tissues and cancer cell-line models. H3-3B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, H3-3B is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, H3-3B RNA expression shows 18,702 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where H3-3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H3-3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H3-3B survival associations across molecular data types. H3-3B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H3-3B RNA expression–survival associations across cancer types. High H3-3B expression shows unfavorable associations in ACC, KIRP, KICH, PAAD and THCA, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for H3-3B RNA expression.
This table summarizes H3-3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for H3-3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H3-3B shows lower tumor expression in KICH, UCEC and PRAD and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher H3-3B RNA expression in tumor versus normal tissue (log2 FC = +0.639, t-test p < 0.001).
This table shows molecular features associated with H3-3B in patient tissues and cancer cell lines. In patient samples, H3-3B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, H3-3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
